Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

ing cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

PEGINTRON is indicated for use in combination with REBETOL (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease.

The following points should be considered when initiating therapy with PEGINTRON in combination with REBETOL:

(1) These indications are based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose.

(2) Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection.

(3) No safety and efficacy data are available for treatment of longer than one year.

PEGINTRON is also indicated for use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age.

The following points should be considered when initiating therapy with PEGINTRON alone: Combination therapy with REBETOL is preferred over PEGINTRON monotherapy unless there are contraindications to, or significant intolerance of, REBETOL. Combination therapy provides substantially better response rates than monotherapy.

Important Safety Information on PEGINTRON

WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS

Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... What can be expected from the ... grow at the fastest rates? Visiongain ,s brand ... data, trends, opportunities and prospects there. Our ... graphs. Discover the most lucrative areas in the industry ... you assess forecasted sales at overall world market and ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... 2011 The University of California, Los Angeles (UCLA) ... soon become the third oncology research center in the ... a privately held medical device company. ViewRay,s new research ... patented combination of radiotherapy delivery and simultaneous magnetic resonance ...
... Nearly three quarters of the medical ... from developed markets, but the next wave of growth is ... unique needs of the India market, according to preliminary findings ... which were presented today at AdvaMed 2011, the annual MedTech ...
Cached Medicine Technology:UCLA Health System - Jonsson Comprehensive Cancer Center to Acquire ViewRay Radiation Therapy Research System 2Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 2Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 3
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be ... As discussed in a June 8, 2015 article published by Nasdaq , the ... been caused by its computer-driven cars, which such industry players as Tesla CEO Elon ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ” ... a look at small, medium, and large businesses making an impact in their ... business review and shared with viewers how DevExpress has provided software development tools ...
(Date:7/30/2015)... ... , ... 24/7 Care At Home, a high-quality provider of comprehensive home health ... Centers for Medicare and Medicaid (CMS) have awarded its agency the highest star rating ... Home’s agency is one of three top Orange County agencies to earn the 5-Star ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never greater than ... to patients as well as visiting friends and family during these critical moments, hospitals ... The stations - powered by ChargeItSpot , a Philadelphia-based startup that recently secured ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s extensive ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects ... editorial and marketing groups will help spread the news about the center’s leading-edge ...
Breaking Medicine News(10 mins):Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... Financial Flexibility - , , LAVAL, QC, June 25 ... ) today announced it has amended its debt facility agreement ... ). , Based on regulatory approval and recent launch of ... has been able to establish more favourable repayment terms. Under ...
... , Social commentator and vegan Ben Shaberman collects humorous ... , BALTIMORE, June 25 Apprentice House announces publication ... which guides readers through the world of being vegan, ... world of carnivores. Whether explaining how vegetarian guys ...
... , Product innovation designed to meet growing consumer demand for ... new line of High Fiber soups from Progresso(R), available in ... for taste, nutritional value and variety among ready-to-serve soups. , ... ingredient to positively impact health, 9 in 10 Americans are ...
... Can Help Americans Improve their Diets, Health and Energy , , NEW YORK, ... Friedrich today announced they are teaming up to help Americans make fitness and healthy ... and exercise, the partners will debut their " EB to ... etter + E at ...
... ... published in the British Journal of Nutrition (a Cambridge University Journal), clearly shows that ... , ... 2009 -- In a revolutionary healthcare finding, a peer-reviewed clinical study published in the ...
... , ... effort to more accurately reflect the service their Recruiters provide and the relationships they ... of their Recruiters to Career Consultants. , ... Omaha, NE (PRWEB) June 25, 2009 -- In an effort ...
Cached Medicine News:Health News:Labopharm amends debt facility agreement with Hercules 2Health News:Labopharm amends debt facility agreement with Hercules 3Health News:The Vegan Monologues Asks the Burning Question: Is That a Carrot in Your Pocket? 2Health News:Progresso(R) to Launch New High Fiber Soup Line in Fall 2009 2Health News:Eggland's Best and Award-Winning Fitness Trainer Cathe Friedrich Launch National Health and Fitness Program 2Health News:Eggland's Best and Award-Winning Fitness Trainer Cathe Friedrich Launch National Health and Fitness Program 3Health News:Eggland's Best and Award-Winning Fitness Trainer Cathe Friedrich Launch National Health and Fitness Program 4Health News:New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33% 2Health News:Traveling Healthcare Staffing Company, Medical Solutions, Announces a Ttitle change for its Recruiters to Career Consultants 2Health News:Traveling Healthcare Staffing Company, Medical Solutions, Announces a Ttitle change for its Recruiters to Career Consultants 3
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... high throughput primary or backup instrument, ... performance and reliability equal to or ... The advanced technology of the AUTION ... delivers reproducible and accurate results, limiting ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... Estrone Sulfate (E1S) is the most abundant ... as normal men [1,2]. Estrone Sulfate is ... and has a longer half-life in blood ... generally parallel those of estrone and estradiol, ...
Medicine Products: